Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma

Journal of Immunotherapy

Volumn 40, Issue 2, 2017, Pages 77-82

  Bricout, Marion ^a   Petre, Adeline ^b   Amini Adle, Mona ^b   Bezza, Widad ^a   Seve, Pascal ^a   Kodjikian, Laurent ^c   Dalle, Stéphane ^b   Thomas, Luc ^b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CROIX ROUSSE HOSPITAL   (France)

Author keywords

anti PD 1; immunotherapy; melanoma; toxicity; uveitis; Vogt Koyanagi Harada syndrome

Indexed keywords

BETAMETHASONE; CARBOPLATIN; DACARBAZINE; DEXAMETHASONE; FOTEMUSTINE; HLA DR4 ANTIGEN; HLA DRB1 ANTIGEN; METHYLPREDNISOLONE; PACLITAXEL; PEMBROLIZUMAB; PREDNISONE; HLA-DRB1*04 ANTIGEN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ANHIDROSIS; ANTERIOR EYE CHAMBER; ARTICLE; ASEPTIC MENINGITIS; AXILLARY LYMPH NODE; BEST CORRECTED VISUAL ACUITY; BLURRED VISION; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; CEREBROSPINAL FLUID; CHOROID DETACHMENT; CYTOLOGY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; EFFUSION; EYE INFLAMMATION; EYE REDNESS; FINGER AMPUTATION; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HAND TUMOR; HUMAN; HUMAN CELL; IMMUNITY; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; LYMPH NODE METASTASIS; LYMPHOCYTIC ASEPTIC MENINGITIS; MALE; MELANOCYTE; METASTATIC MELANOMA; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PAPILLEDEMA; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA DETACHMENT; RETINAL NERVE FIBER LAYER THICKNESS; SKIN METASTASIS; SLIT LAMP MICROSCOPY; SUBRETINAL FLUID; SWEAT GLAND DISEASE; TUMOR GROWTH; VISUAL DISORDER; VISUAL IMPAIRMENT; VITILIGO; VOGT KOYANAGI SYNDROME; ADVERSE DRUG REACTION; DRUG RESISTANCE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; MENINGOENCEPHALITIS; PROCEDURES; SECONDARY; SKIN TUMOR; UVEITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE, NEOPLASM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC PREDISPOSITION TO DISEASE; HLA-DR4 ANTIGEN; HLA-DRB1 CHAINS; HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; MALE; MELANOCYTES; MELANOMA; MENINGITIS, ASEPTIC; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; UVEITIS; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 85011632555     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000154     Document Type: Article

References (31)

1. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.
2. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330.
3. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372: 2521-2532.
4. Khoja L, Butler MO, Kang SP, et al. Pembrolizumab. J Immunother Cancer. 2015;3:36.
5. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559-574.
6. Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152:45-51.
7. Bouwhuis MG, Ten Hagen TLM, Suciu S, et al. Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol. 2011;23:170-176.
8. Bouwhuis MG, ten Hagen TLM, Eggermont AMM. Immunologic functions as prognostic indicators in melanoma. Mol Oncol. 2011;5:183-189.
9. Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151:1206-1212.
10. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4:560-575.
11. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219-242.
12. Schmerling RA. Toxicity of checkpoint inhibitors. Chin Clin Oncol. 2014;3:31.
13. Miserocchi E, Cimminiello C, Mazzola M, et al. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol. 2015;50:e2-e4.
14. Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol. 2016;51:e4-e6.
15. Abu Samra K, Valdes-Navarro M, Lee S, et al. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2016;26:e46-e48.
16. Robinson MR, Chan C-C, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004;27:478-479.
17. Jacobsoone-Ulrich A, Jamme P, Alkeraye S, et al. Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases. Melanoma Res. 2016;26:153-156.
18. Khoja L, Atenafu EG, Ye Q, et al. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncol Lett. 2016;11:1581-1585.
19. Yeh S, Karne NK, Kerkar SP, et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009;116:981.e1-989.e1.
20. Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)- induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome. Retin Cases Brief Rep. 2012;6:423-426.
21. Crosson JN, Laird PW, Debiec M, et al. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother. 2015;38:80-84.
22. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-652.
23. Teulings H-E, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33:773-781.
24. Wang C, Tian Y, Lei B, et al. Decreased IL-27 expression in association with an increased Th17 response in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012;53: 4668-4675.
25. Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 1996;80:1002-1008.
26. Lavezzo MM, Sakata VM, Morita C, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis. 2016;11:29.
27. Shi T, Lv W, Zhang L, et al. Association of HLA-DR4/HLADRB1∗ 04 with Vogt-Koyanagi-Harada disease: a systematic review and meta-analysis. Sci Rep. 2014;4:6887.
28. Ng JY, Luk FO, Lai TY, et al. Influence of molecular genetics in Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. 2014;4:20.
29. Du L, Yang P, Hou S, et al. Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome. Clin Immunol. 2008; 127:43-48.
30. Meng Q, Liu X, Yang P, et al. PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome. Mol Vis. 2009;15: 386-392.
31. Modorati G, Matteo DF, Miserocchi E, et al. Serous retinal detachments complicating interferon-a and ribavirin treatment in patients with hepatitis C. Case Rep Ophthalmol. 2011;2:105-110.